SNY - French Pharma Giant Sanofi's Q4 Earnings Hit By Aubagio Generic Competition Helped By Flagship Eczema And Newly Launched Hemophilia Drugs | Benzinga
Sanofi SA (NASDAQ:SNY) says its fourth-quarter operating income fell 5.2% to €2.6 billion, up 5.3% on constant currency.
Revenues increased 1.8% to €10.92 billion ($11.75 billion), up 9.3% on constant currency, missing the consensus of $12.26 billion.
Specialty Care grew 13.7%, driven by the Dupixent and Altuviiio launch, more than offsetting competition from Aubagio generics in all key markets.
“At the same time, we are taking steps to become a pure-play biopharma company with more than €10bn sales contribution from Pharma launches by 2030,” commented CEO Paul Hudson.
Also Read: Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January.
In January, Sanofi agreed to acquire ...